Xarelto Update: First Federal MDL Trial Verdict

May 11th, 2017

The first multi-district litigation (MDL) trial for the blood thinner medication Xarelto began just a few weeks ago. This drug is used to prevent blood clots in patients suffering from arrhythmic heart disorder. If not properly monitored, Xarelto increases the risk of severe internal bleeding. The legal team representing Xarelto victims argues that the manufacturer of the drug failed to properly warn the medical community of the danger of uncontrollable bleeding presented by Xarelto. Sadly, there is no known antidote or treatment to stop the bleeding resulting from Xarelto use. This defective drug has shattered the lives of thousands of innocent persons who took Xarelto and suffered serious injuries and death from excessive gastrointestinal and cranial bleeding.

On May 3, 2017, a Louisiana federal court jury ruled in favor of the manufacturer of Xarelto, Bayer Pharmaceuticals, a subsidiary of Johnson & Johnson. This is the first of four MDL cases to be tried over the next several months. The case was decided by the jury based on the learned intermediary doctrine, a legal principle which limits the responsibility of drug manufacturers to warn individual patients. Under this doctrine, the manufacturer is only obligated to appropriately advise medical professionals about the drug’s dangerous side effects. Although the jury’s recent verdict is disappointing, their decision has absolutely no bearing on future cases. Lawyers will continue to press forward in the fight to obtain justice for Xarelto victims.

There are over 18,000 other Xarelto lawsuits currently pending in the United States. Attorneys for Xarelto victims continue to maintain that the manufacturer of this defective drug breached its legal duty to fully warn users of the dangerous risks of Xarelto. With the large number of lawsuits filed by victims suffering from the serious complications of taking Xarelto, Bayer and Johnson & Johnson will face considerable pressure to be held responsible for their defective drug in the upcoming MDL trials.

Our experienced lawyers fight for individuals who have been harmed by defective drugs. If you or a loved one has suffered from serious internal bleeding after using the blood thinner Xarelto, the attorneys at the Yost Legal Group will investigate the claim. For a free consultation, please call us at 1-800-YOSTLAW. At The Yost Legal Group, there is no fee or expense unless you recover.

Metal-on-Metal Hip Implants and Metallosis

Metal poisoning occurs when toxic levels of metal build up in the body causing damage to tissues, bones, and the nervous system. One type of metal poisoning, called metallosis, can occur as a side effect of joint replacement surgery using metal components such as those in metal-on-metal hip implants. Medical device manufacturers like Smith & Nephew, Zimmer, DePuy, and Stryker began releasing metal-on-metal hip implants in 2006. Since that time, thousands of individuals have experienced…

Read More »

AbbVie Hit with $150M Verdict in “Low-T” Trial

The first jury verdict in a series of bellwether trials involving the testosterone treatment AndroGel is in. The jury found that the manufacturer of the gel, AbbVie, should pay $150 million in punitive damages to Oregon resident Jesse Mitchell. After seeing a commercial about AndroGel and using the product for 4 years, Mr. Mitchell suffered a nearly fatal heart attack. He testified that he would not have used the drug if AbbVie had properly warned…

Read More »

How Risperdal Changes Lives

At The Yost Legal Group, we have extensive experience standing up to major pharmaceutical manufacturers. We are currently representing young men and boys who were harmed by Johnson & Johnson by using the medication Risperdal which was supposed to make their lives more manageable. Instead, they are now forced to deal with the embarrassing symptoms of the Risperdal side effect gynecomastia, which causes enlarged breasts, tenderness and sensitivity, and nipple discharge. One of our clients, who…

Read More »

First Testosterone Gel Trial to Begin in June

The first of seven multidistrict litigation (MDL) trials involving testosterone therapy gel products begins on June 5, 2017 in the U.S District Court for the Northern District of Illinois.  About 7,000 individual cases have been filed in this MDL. The Plaintiffs allege that over a dozen pharmaceutical companies unethically and aggressively marketed testosterone replacement therapy drugs to treat symptoms of normal male aging. AbbVie Inc. and Abbott Laboratories face most of the claims in the…

Read More »